The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia
阿片类糖肽 MMP-2200 与 NMDA 受体拮抗剂的组合可减轻 l-DOPA 引起的运动障碍，而 MMP-2200 本身可减轻多巴胺受体 2 样激动剂引起的运动障碍
期刊:Neuropharmacology
影响因子:4.6
doi:10.1016/j.neuropharm.2018.09.005
Andrew J Flores, Mitchell J Bartlett, Brandon K Root, Kate L Parent, Michael L Heien, Frank Porreca, Robin Polt, Scott J Sherman, Torsten Falk
